Skip to main content
. 2021 Feb 22;2021:6623093. doi: 10.1155/2021/6623093

Table 1.

Characteristics of the COPD cohort.

All COPD N = 637 Comparison based on prior AHRF in COPD
No AHRF N = 323 AHRF N = 314 p
Age (years) 74 (66–80) 75 (68–82) 65 (73–78) <0.01
Sex (male) 278 (43.6) 148 (45.8) 140 (44.59) 0.75
Pack years 40 (33–56) 40 (32–55) 40 (33–56) 0.59
Current smokers 126 (19.8) 49 (15.2) 77 (24.5) 0.02
Hypercapnia 233 (36.6) 73 (22.6) 145 (46.18) <0.01
BMI 25.5 (213–32.5) 24.6 (21.3–32.0) 26·7 (21.4–33.6) 0.28
FEV1 0.9 (0.65–1.26) 0.98 (0.72–1.43) 0·82 (0.59–1.12) <0.01
FEV1pp 41 (41–55) 47 (34–60) 36 (28–49) <0.01
FVCpp 73 (57–90) 78 (63–94) 69 (51–85) <0.01
DLCOpp 48.9 (38.9–73.3) 60.9 (55.1–66.7) 43.6 (36.2–64.9) <0.01
RVpp 104.35 (89.5–123.4) 100 (88.03–108.93) 112 (93.4–134.25) 0.09
PaO2 7.9 (7.1–8.7) 7.9 (7.2–8.7) 7.8 (7.0–8.6) 0.08
PaCO2 5.9 (4.9–6.9) 5.5 (4.7–6.4) 6.4 (5.4–7.5) <0.01
HCO3 28.4 (26.2–31.5) 27.5 (25.6–30.1) 29 (26.7–32.8) <0.01
BE 3.7 (1.5–6.5) 3.4 (1.2–5.7) 4.3 (2.3–7.2) <0.01
On LTOT 304 (47.7) 146 (45.2) 158 (50.3) 0.2
Emphysema 284 (44.6) 177 (54.8) 142 (45.2) 0.04
Upper lobe emphysema 113 (39.8) 58 (51.3) 55 (48.7) 0.21
Lower lobe emphysema 14 (4.9) 12 (85.7) 2 (14.3) 0.12
No zonal predominance 157 (55.3) 89 (56.69) 68 (43.3) 0.79
LZVI-UZVI
Bronchiectasis 101 (15.9) 50 (15.5) 51 (16.2) 0·79
Change in FEV1/ml/year −54 (−160-23.5) −65.5 (−172.8-8) −49 (−143.5−32.5) 0·33
Follow-up (years) 1.33 (0.31–2.65) 1.30 (0.31–2.56) 0.31 (1.34–2.87) 0·62
Death 415 (65.1) 192 (59.4) 223 (71.02) <0.01

Data are shown as mean (SE) or median (IQR) for quantitative measures, and n (%) for binary outcomes, which are further denoted by italic text.